Failed, Inconclusive or Interrupted Trials in Multiple Sclerosis: 2020-2024 Update

Area of Science:

• Neuroimmunology
• Clinical Pharmacology
• Translational Medicine

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease impacting millions globally.
• Current treatments address inflammation but not neurodegeneration, progression, or remyelination.
• Significant unmet needs persist despite therapeutic advances.

Purpose of the Study:

• To analyze clinical trials for multiple sclerosis (MS) that failed due to negative or inconclusive results.
• To identify trends and challenges in MS drug development between October 2019 and October 2024.
• To understand reasons behind trial failures to guide future therapeutic strategies.

Main Methods:

• Conducted a literature review of MEDLINE, clinical trial databases, and conference proceedings.
• Identified and analyzed failed Phase I-III and randomized controlled trials (RCTs) based on primary endpoints.
• Excluded studies focusing solely on secondary MS outcomes like spasticity or cognitive impairment.

Main Results:

• 17 investigational agents across seven classes (e.g., immune-active, neuroprotective, remyelination antibodies) were identified.
• While some agents showed biological activity (e.g., reduced MRI lesions, improved VEPs), none met primary endpoints.
• Reasons for failure included safety concerns, heterogeneous patient populations, and insensitive endpoints.

Conclusions:

• Novel MS therapies demonstrate mechanistic promise but face significant hurdles in achieving durable clinical outcomes.
• Key challenges include addressing disability accumulation, ensuring drug tolerability, promoting repair, and achieving commercial viability.
• Further research is needed to overcome these barriers and develop more effective MS treatments.